Unknown

Dataset Information

0

Surface cysteine to serine substitutions in IL-18 reduce aggregation and enhance activity.


ABSTRACT:

Background

Interleukin-18 (IL-18) is prone to form multimers resulting in inactive aggregates, making this cytokine unstable for clinical use. Therefore, mutations have been introduced into recombinant IL-18 to overcome this issue.

Methods

To prevent the formation of disulfide bonds between the IL-18 molecules, multiple mutations targeting surface cysteines (C38, C68, C76, and C127) were introduced into our previously modified human IL-18 double mutant E6K+T63A (IL-18 DM) by direct gene synthesis. The open reading frames of IL-18 wild-type (WT), IL-18 DM, and IL-18 multiple mutant E6K+T63A+C38S+C68S+C76S+C127S (IL-18 DM1234) were inserted in the pET28a expression vector and transformed into Escherichia coli Rosetta2 (DE3) pLysS cells for protein production. The inclusion bodies of WT and mutated IL-18 were extracted by sonication and refolded by stepwise dialysis using 8 M urea as the starting concentration. The refolded IL-18 proteins were tested for aggregation using the ProteoStat protein aggregation assay. Their activity was also investigated by treating NK-92MI cells with each IL-18 at concentrations of 75, 150, and 300 ng/ml with 0.5 ng/ml of human IL-12 and interferon-gamma (IFN-γ) levels in the supernatant were evaluated using ELISA. The structure of modified IL-18 was visualized using molecular dynamics (MD) simulations.

Results

IL-18 DM1234 exhibited the lowest aggregation signal, approximately 1.79- and 1.63-fold less than that of the WT and IL-18 DM proteins. Additionally, the IFN-γ inducing activity of IL-18 DM1234 was about 10 and 2.8 times higher than that of the WT and IL-18 DM, respectively. MD simulations revealed that binding site I of IL-18 DM1234 was altered mainly due to surface cysteine replacement with serine (C-to-S substitution). This is the first report showing that C-to-S substitutions in IL-18 improved its activity and stability, suggesting the use of this modified IL-18 for medical purposes in the future.

SUBMITTER: Saetang J 

PROVIDER: S-EPMC9266699 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC129755 | biostudies-literature
| S-EPMC3286296 | biostudies-literature
| S-EPMC5957530 | biostudies-literature
| S-EPMC6554436 | biostudies-literature
| S-EPMC8234286 | biostudies-literature
2016-07-21 | E-GEOD-84636 | biostudies-arrayexpress
| S-EPMC3253181 | biostudies-literature
| S-EPMC5016662 | biostudies-literature
| S-EPMC5120207 | biostudies-literature
| S-EPMC2775217 | biostudies-literature